Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTaxot in high- and very high-risk prostate cancer
2010-019139-36Phase 2Active
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- Apr 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoints: 5-year biochemical control rate and Safety and tolerability. Started Apr 2010; status: active.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-019139-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019139-36.